Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: Relation to hemodynamic response

American Journal of Cardiology

Volumn 83, Issue 12 B, 1999, Pages 12-15

  Nicklas, John M ^a   Monsur, Joseph C ^a   Bleske, Barry E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; LEVOSIMENDAN; NORADRENALIN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033600153     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00312-4     Document Type: Conference Paper

References (29)

1. Thomas J.A., Marks B.H. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 41:1978;233-243.
2. Levine T.B., Francis G.S., Goldsmith S.R., Simon A.B., Cohn J.N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 49:1982;1659-1666.
3. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
4. Remes J., Tikkanen J., Fyhrquist F., Pyörälä K. Neuroendocrine activity in untreated heart failure. Br Heart J. 65:1991;249-255.
5. Dzau V.J. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol. 70:(suppl C):1992;4C-11C.
6. Francis G.S., McDonald K.M., Cohn J.N. Neurohormonal activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation. 87:(suppl 41):1993;IV-90-IV-96.
7. Sigurdsson A., Swedberg K. Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure? Br Heart J. 72:(September):1994;75-80.
8. Francis G.S., Benedict C.F., Johnstone D.E. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 82:1990;1724-1729.
9. Benedict C.R., Johnstone D.E., Weiner D.H. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction a report from the registry of Studies of Left Ventricular Dysfunction . J Am Coll Cardiol. 23:1994;1410-1420.
10. Broqvist M., Dahlström U., Karlberg B.E., Karlsson E., Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 10:1989;1075-1083.
11. Kaye D.M., Lefkovits J., Jennings G.L., Bergin P., Broughton A., Esler M.D. Adverse consequences of high sympathetic nervous activity in the failing heart. J Am Coll Cardiol. 26:1995;1257-1263.
12. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W.B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med. 325:1991;303-310.
13. Francis G.S., Cohn J.N., Johnson G., Rector T.S., Goldman S., Simon A. Plasma norepinephrine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation. 20:1993;248-254.
14. Packer M. Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J. 16:(suppl F):1995;4-6.
15. Shan K., Kurrelmeyer K., Seta Y., Wang F., Dibbs Z., Deswal A., Lee-Jackson D., Mann D.L. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol. 12:1997;218-223.
16. Hickey K.A., Rubany G., Paul R.J., Highsmith R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 248:1985;C550-C556.
17. Takuwa Y, Yanagisawa M, Takuwa N, Masaki T. Endothelin, its diverse biological activities and mechanisms of action. PhD Thesis, Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan, 1989.
18. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., Chien K.R. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem. 265:1990;20555-20562.
19. Ito H., Hirata Y., Hiroe M., Tsujino M., Adachi S., Takamoto T., Nitta M., Taniguchi K., Marumo F. Endothelin-1 induces hvpertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 69:1991;209-215.
20. Tsutamoto T., Wada A., Maeda Y., Adachi T., Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 23:1994;1427-1433.
21. Sakai S., Miyauchi T., Sakurai T., Kasuya Y., Ihara M., Yamaguchi I., Goto K., Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure marked increase in endothelin-1 production in the failing heart . Circulation. 93:1996;1214-1222.
22. Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G., Brandt R.R., Wright S., Heublein D.M., Kao P.C., Edwards W.D., Burnett J.C. Jr. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
23. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
24. Kiowski W., Sutsch G., Hunziker P., Muller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1 mediated vasoconstriction in severe heart failure. Lancet. 346:1995;732-736.
25. Ito H., Hiroe M., Hirata Y., Fujisaki H., Adachi S., Akimoto H., Ohta Y., Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 89:1994;2198-2203.
26. Shimoyama H., Sabbah H.N., Borzak S., Tanimura M., Shevlyagin S., Scicli G., Goldstein S. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation. 94:1996;779-784.
27. Tohmo H., Karanko M., Korpilahti K., Scheinin M., Viinamaki O., Neuvonen P. Enalaprilat in acute intractable heart failure after myocardial infarction a prospective, consecutive sample, before and after . Crit Care Med. 22:1994;965-973.
28. Davidson N.C., Coutie W.J., Webb D.J., Struthers A.D. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart. 75:1996;576-581.
29. Krum H., Gu A., Wilshire-Clement M., Sackner-Bernstein J., Goldsmith R., Medina N., Yushak M., Miller M., Packer M. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J. 13:1996;337-341.